Celldex Therapeutics Inc
$ 24.84
2.14%
24 Feb - close price
- Market Cap 1,616,051,000 USD
- Current Price $ 24.84
- High / Low $ 25.11 / 24.18
- Stock P/E N/A
- Book Value 9.01
- EPS -3.38
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.32 %
- 52 Week High 30.50
- 52 Week Low 14.40
About
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
Analyst Target Price
$53.36
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-07 | 2025-05-05 | 2025-02-24 | 2024-10-31 | 2024-08-08 | 2024-05-06 | 2024-02-26 | 2023-11-02 | 2023-08-08 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 | -0.81 | -0.65 | -0.62 | -0.56 |
| Estimated EPS | -0.9 | -0.86 | -0.69 | -0.7146 | -0.67 | -0.59 | -0.69 | -0.74 | -0.68 | -0.67 | -0.63 | -0.59 |
| Surprise | -0.11 | 0.01 | -0.12 | 0.0046 | 0.03 | 0.05 | 0.13 | -0.09 | -0.13 | 0.02 | 0.01 | 0.03 |
| Surprise Percentage | -12.2222% | 1.1628% | -17.3913% | 0.6437% | 4.4776% | 8.4746% | 18.8406% | -12.1622% | -19.1176% | 2.9851% | 1.5873% | 5.0847% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.0 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLDX
2026-02-23 13:20:27
Celldex (NASDAQ: CLDX) announced it will present multiple Phase 2 barzolvolimab datasets at the AAAAI Annual Meeting from Feb 27–Mar 2, 2026, in Philadelphia. These presentations will cover chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD), including a late-breaker open-label extension (OLE) retreatment analysis showing rapid symptom control. The company is advancing barzolvolimab into Phase 3 studies in CSU and ColdU/SD, and also has ongoing Phase 2 studies in prurigo nodularis (PN) and atopic dermatitis (AD).
2026-02-23 13:20:27
Celldex (NASDAQ: CLDX) announced upcoming presentations at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting, highlighting new data from its Phase 2 clinical trials of barzolvolimab. The presentations will cover barzolvolimab's efficacy in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD), including late-breaker data showing rapid improvement in urticaria control upon retreatment. Barzolvolimab is a humanized monoclonal antibody targeting the KIT receptor on mast cells, demonstrating potential as a first-in-class treatment and is currently in Phase 3 studies.
2026-02-23 12:46:35
Celldex Therapeutics announced several presentations related to its drug barzolvolimab at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting. The presentations will include new data from Phase 2 clinical trials for chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD), highlighting barzolvolimab's efficacy and retreatment benefits. Barzolvolimab, a first-in-class mast cell inhibitor, is currently in Phase 3 studies for CSU and ColdU/SD, with additional indications under investigation.
2026-02-19 11:27:23
Readystate Asset Management LP significantly reduced its stake in Celldex Therapeutics Inc. by selling 288,480 shares, an 86.1% decrease, during the third quarter, retaining 46,520 shares valued at approximately $1.2 million. Despite this sale, analyst sentiment for Celldex Therapeutics is generally positive, with a "Moderate Buy" consensus and an average price target of $41.56, though ratings vary. The biopharmaceutical company focusing on immunotherapies for cancer is currently trading around $23, with a market capitalization of $1.53 billion.
2026-02-19 06:57:39
Celldex Therapeutics (CLDX) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts anticipating a loss of ($1.00) per share and revenue of $1.533 million. The company's stock opened at $23.00, trading within a 52-week range of $14.40 to $30.50, and holds a "Moderate Buy" consensus rating from analysts with an average price target of $41.56, despite some divergent views from firms like Barclays and Weiss. Institutional investors have also been active, with several increasing positions or buying new shares in CLDX during recent quarters.
2026-02-13 00:27:23
Celldex announced that its management will participate in three upcoming investor conferences in February and March 2026. The company will present at the Guggenheim Emerging Outlook: Biotech Summit, TD Cowen 46th Annual Health Care Conference, and Leerink Global Healthcare Conference. Live webcasts and replays of these presentations will be available on the Celldex website.
